Focus on recalibrating your approach with small, consistent changes
Avoid exposing the medication to extreme temperatures, direct sunlight, or freezing
Neuropsychiatric effects have been reported in post-marketing surveillance of GLP-1 receptor agonists, though the incidence and causal relationship remain unclear
In the U.S., an estimated 5.1% of non-Hispanic White patients with obesity use GLP-1s, compared to 4.5% of Asian patients, 4.1% of non-Hispanic Black patients, 4.0% of Native American patients, and 3.7% of Hispanic patients
While weight loss may provide significant joint symptom relief over time, this benefit typically emerges gradually over months as weight reduction accumulates
This temporary program serves as an important test case that may pave the way for more permanent coverage solutions in the future